Parkinson’s drug therapies in the clinical trial pipeline: 2024 update
Each year, members of the Cure Parkinson’s research team collaborate with Parkinson’s research advocates and The Michael J. Fox Foundation to present an overview on the current clinical trials landscape for Parkinson’s. The 2024 report, now published in the Journal of Parkinson’s Disease (JPD), marks...
Learn more
Preliminary phase 2 trial results of lixisenatide presented
A one-year, phase 2 clinical trial of Type 2 diabetes drug lixisenatide has reported positive early results, which indicate that the treatment may slow the progression of motor (or movement) symptoms. Preliminary results of the LixiPark study were presented at the International Parkinson and Movement…
Aspen starts phase 1 stem cell transplant clinical trial
An experimental treatment for Parkinson’s involves the replacement of the lost dopamine neurons by transplanting new cells into the brain. Biotech company Aspen Neuroscience will soon be starting a clinical trial in the US exploring this potential therapy in people with Parkinson’s.
New data supporting neurotrophic factor as a potential treatment for Parkinson’s
An article in the Journal of the International Movement Disorders Society reports on some pre-clinical (laboratory) data supporting the development of ‘Glial cell line-Derived Neurotrophic Factor’ (GDNF) as a potential disease-modifying treatment for Parkinson’s.
The 2023 International Linked Clinical Trials meeting
In June, Cure Parkinson’s gathered 23 of the world’s leading Parkinson’s experts together for the annual International Linked Clinical Trials (iLCT) meeting. The iLCT committee was created in 2012 through a collaboration between Cure Parkinson’s and Van Andel Institute with the goal of prioritising potential…
Positive phase 1 results for BlueRock
BlueRock Therapeutics has reported positive results from the phase 1 trial of its cell-replacement therapy for Parkinson’s